Hepatocellular carcinoma (HCC) is the most predominant form of liver cancer and the third leading cause of cancerrelated death worldwide. Due to the relative ineffectiveness of conventional HCC therapies, oncolytic viruses have emerged as novel alternative treatment agents. Our previous studies have demonstrated significant prolongation of survival in advanced HCC in rats after oncolytic vesicular stomatitis virus (VSV) treatment. In this study, we aimed to establish a reporter system to reliably and sensitively image VSV in a clinically relevant model of HCC for clinical translation. To this end, an orthotopic, unifocal HCC model in immune-competent Buffalo rats was employed to test a recombinant VSV vector encoding for an enhanced version of the herpes simplex virus 1 (HSV-1) thymidine kinase (sr39tk) reporter, which would allow the indirect detection of VSV via positron emission tomography (PET). The resulting data revealed specific tracer uptake in VSV-HSV1-sr39tk-treated tumors. Further characterization of the VSV-HSV1-sr39tk vector demonstrated its optimal detection time-point after application and its detection limit via PET. In conclusion, oncolytic VSV expressing the HSV1-sr39tk reporter gene allows for highly sensitive in vivo imaging via PET. Therefore, this imaging system may be directly translatable and beneficial in further clinical applications.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a globally spread malignant disease with rising incidence in the United States and Europe. [1] [2] [3] Curative treatments are limited to liver resection, local ablation or liver transplantation, for which only a very small percentage of patients are candidates. Most patients present themselves with advanced disease at the time of detection and are only eligible for palliative treatments, which offer poor prognoses. [2] [3] [4] This situation ranks HCC the third leading cause of cancer-related death worldwide, 5, 6 and novel treatment options are urgently needed.
Oncolytic virus (OV) therapy is a promising new strategy in cancer therapy. OVs are naturally occurring viruses named for their property to preferentially replicate in cancerous cells, while leaving healthy cells mainly unaffected. 7 With increasing momentum over the last 15 years, OVs have been in the focus of cancer research, and their overall success has been well documented 8, 9 and has culminated in a wave of clinical trials of many different vector platforms for various cancers, including HCC. [10] [11] [12] [13] One such promising OV is vesicular stomatitis virus (VSV). 14 Our previous studies have demonstrated significant prolongation of survival in HCC-bearing rats after VSV treatment. [15] [16] [17] More recently, we have reported that VSV treatment of HCC in the clinically relevant context of hepatic fibrosis, is not only safe, but it also provides a therapeutic benefit to the underlying liver pathology. 18 Additionally, a phase 1 clinical trial, using recombinant VSV expressing interferon-β, 19 has recently been initiated in primary liver cancer patients (ClinicalTrials.gov Identifier: NCT01628640). As VSV virotherapy for HCC is becoming a reality, the necessity of a system to enable noninvasive and real-time monitoring of virus replication and biodistribution in patients has become apparent.
Noninvasive imaging is a technology, which allows us to monitor processes occurring inside the body without applying invasive procedures such as biopsies. Hybrid imaging of PET (positron emission tomography) and CT (computed tomography) is a modality routinely applied in the clinic, where the CT provides anatomical background information, while biological processes are detected by PET. PET enables the quantitative detection of radiotracers on a molecular level and, therefore, is suitable for monitoring biological processes via artificially introduced reporters, 20 such as the herpes simplex virus 1 (HSV1) thymidine kinase (TK). Vectors equipped with HSV1-TK are detectable by PET after application of an appropriate radionuclide-labeled tracer. Various radiotracers are available for the detection of the TK reporter by PET. 21, 22 Although wild-type (wt) TK has been used for the detection of intrahepatic targets before in combination with other tracers, 23, 24 we decided to exploit a mutant version of this reporter, sr39tk, which has been shown to have enhanced 18 F-FHBG has been successfully applied in imaging studies with hepatic targets, which can present unique challenges due to high background signals. 26, 27 Importantly, 18 F-FHBG has been defined as one of the most favorable tracers for detection of the TK reporter, showing superior selectivity in comparison to other tracers. 28, 29 Additionally, its safety was defined preclinically, and favorable pharmacokinetics and dosimetry have been demonstrated in humans. 30, 31 For this reason, we have engineered a recombinant VSV vector encoding the HSV1-sr39tk reporter (rVSV-HSV1-sr39tk) and tested its potential for noninvasive imaging of the virus in a clinically relevant model of orthotopic HCC in immune-competent rats.
Since the efficacy of various recombinant oncolytic VSV vectors in this HCC model has already been extensively demonstrated by our group, [15] [16] [17] this study concentrates exclusively on the establishment of the noninvasive in vivo imaging of the newly established reporter virus. Our results demonstrate that this system is highly sensitive, with minimal background in the liver setting, and allows for accurate monitoring of virus replication and distribution via 18 F-FHBG-PET and CT. These data support the application of the HSV1-sr39tk reporter for imaging of oncolytic VSV therapy in HCC patients in the future.
RESULTS
In vitro characterization of VSV-HSV1-sr39tk and HSV1-sr39tk-expressing stable rat HCC cell line After successful cloning and rescue of rVSV-HSV1-sr39tk, the replication kinetics were assessed by in vitro multicycle and onestep growth curves (MOI: 0.01 and 10, respectively), using the previously established rVSV-lacZ as a control. The viral titers of both vectors were indistinguishable at all times points tested, indicating that the expression of the HSV1-sr39tk reporter gene does not alter viral kinetics (Figure 1a) . Additionally, cell survival of rat HCC cells revealed no appreciable difference in the cytotoxicity of rVSV-HSV1-sr39tk as compared to the control vector (Figure 1b) .
For the establishment of PET/CT imaging via the HSV1-tk reporter, an HCC cell line, stably expressing the reporter was generated to serve as a positive control. To confirm HSV-1-sr39tk protein expression in virus-infected and stably transfected cells, immunofluorescence microscopy ( Figure 1c) and Western Blot analysis (Figure 1d) were performed. Both assays revealed protein expression specifically in the stable cell line and rVSV-HSV1-sr39tk-infected cells, while none could be detected in the control samples. Additionally, only the VSV-infected cells showed a positive VSV-G-protein signal.
To test the functionality of the expressed reporter protein, in vitro uptake of 18 F-FHBG was performed. Although untreated wt cells and cells infected with VSV-lacZ showed a very low background FHBG uptake, significantly higher tracer uptake could be detected in the stable cell line, as well as in the rVSV-HSV1-sr39tk-infected cells (Figure 1e) . Stable HSV1-tk-expressing subcutaneous tumors result in significant uptake of 18 
F-FHBG
To establish the PET/CT imaging protocol, animals were implanted with two subcutaneous tumors: a stable HSV1-tk-expressing HCC cell line on the right and the wt HCC cell line on the left shoulder (N = 4). FHBG-PET/CT imaging revealed strong signals in tumors of the stable cell line, while there was no observable signal in wt tumors (Figure 2a) . Quantitative ROI analysis demonstrated a significant FHBG tracer uptake in the stable tk-expressing tumors (Figure 2b) . These findings were confirmed by ex vivo immunohistochemistry and autoradiography. While wt tumors showed no HSV-tk expression by immunohistochemistry and autoradiography, stable tumors showed a positive signal by both methods (Figure 2c) . Importantly, overlaying immunohistochemistry and autoradiography images revealed a colocalization of HSV1-tk expression with tracer uptake. Semiquantitative analysis by autoradiography additionally illustrated a significant tracer uptake only in the stable tumors (Figure 2d ).
Intratumoral injection of rVSV-HSV1-sr39tk results in significant 18

F-FHBG-PET signals in orthotopic HCC
To determine the applicability of rVSV-HSV1-sr39tk imaging to the orthotopic system, intrahepatic HCC tumors were injected with PBS (N = 4), or 10 7 pfu of rVSV-lacZ (N = 2) or rVSV-HSV1-sr39tk (N = 6). As a positive control, a group of rats was implanted with stable HSV1-sr39tk-expressing HCC cells (N = 3). No signal was detected in PBS or VSV-lacZ-treated tumors via FHBG-PET/CT 1 day after treatment, while high tracer uptake could be seen in positive control animals, as well as in rVSV-HSV1-sr39tk-treated animals (Figure 3a) . Semiquantitative ROI analysis of these data revealed significant FHBG tracer uptake in the stable tk-expressing tumors and rVSV-HSV1-sr39tk-treated tumors compared to liver, while control-treated tumors showed no increase (Figure 3b) . To validate these findings, we performed ex vivo immunohistochemistry and autoradiography. Positive staining for HSV-tk could be observed only in tumors of the stable cell line or those treated with rVSV-HSV1-sr39tk, which correlated to areas of tracer uptake on corresponding autoradiography images (Figure 3c ). Semiquantitative analysis of autoradiography data illustrated significant tracer uptakes in the stable tumors and rVSV-HSV1-sr39tk-treated tumors only (Figure 3d ).
The tumor signal in
18
F-FHBG-PET peaks on day 1 after VSV-HSV1-sr39tk treatment To investigate the kinetics of VSV-mediated HSV1-sr39tk imaging, HCC-bearing animals were injected intratumorally with 10 7 pfu VSV-HSV1-sr39tk and imaged either 6 hours (N = 2), 1 day (N = 4) or 3 days (N = 5) after virus treatment by FHBG-PET/ CT (Figure 4a ). While no specific tumor signal could be detected 6 hours after virus application, a strong intratumoral 18 F-FHBG uptake could be detected 1 day after therapy, which was statistically significant by ROI analysis (Figure 4b ). Although tumor ROI values remained statistically significant on day 3, the intensity had decreased to a similar level to that observed after 6 hours, and no tumor signal could be detected visually. This data is consistent with our previous reports describing the replication kinetics of VSV in orthotopic HCC tumors, in which we observed a peak in viral titer on day 1, followed by a reduction by several logs on day 3.
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A viral dose of at least 1 × 10 6 pfu needs to be injected in order to guarantee successful detection of VSV-HSV1-sr39tk by PET To determine the minimal injected viral load to receive a significant FHBG-PET signal, we performed a dose decrement study of VSV-HSV1-sr39tk. Starting at the maximum tolerated dose (MTD) of 10 7 , orthotopic HCC-bearing rats were randomly assigned to receive log-wise dose decrements to a minimum dose of , while lower doses resulted in no appreciable tracer uptake (Figure 5a) . Similarly, quantitative ROI analysis revealed that the intratumoral tracer uptake was statistically significant with a minimum injection dose of 10 6 pfu (Figure 5b) . Importantly, a goodness of fit analysis of PET tumorto-liver ratios versus intratumoral viral titers revealed a strong correlation (R 2 = 0.8880) in animals treated with either 10 6 or 10 7 pfu of VSV-HSV1-sr39tk (Figure 5c ). In order to define a detection limit, the mean tumor-to-liver ratio of PBS-treated animals (N = 6) has been calculated. The mean value plus the standard deviation of this group resulted in y = 1.33 (Figure 5d ). This is considered to be the background signal of untreated tumors, and we define any tumor-to-liver ratio greater than this value to be above the detection limit. To illustrate the signal distribution, intratumoral titers have been depicted against the respective tumor-to-liver-ratio in the individual animals (Figure 5d) . 
DISCUSSION
Over the last decade, substantial progress in the field of oncolytic virus development has enabled the clinical translation of OV therapy to become a reality. In light of this development, the clinical need for an accurate, sensitive, and reproducible method of noninvasively imaging the virus after application to patients has become evident. Such a system would allow clinicians to determine virus replication and biodistribution in real-time to predict the efficacy of the therapy, as well as to monitor safety, and offer the possibility of providing personalized medicine, such that the course of therapy could be altered based on imaging findings. However, noninvasive imaging of replicating viruses in vivo presents a unique set of challenges. Since lysis of cancerous cells occurs rapidly after infection, the time frame, in which the expression of a reporter protein can be exploited for imaging, is very limited. Due to innate differences in the replication kinetics of each vector platform, as well as the time-course of reporter protein expression versus half-life, the optimal time-point for detection of virus-mediated reporter expression needs to be determined individually for each vector and reporter system. To date, numerous reports have described noninvasive imaging of oncolytic viruses in vivo 26, 27, 33 ; however, to our knowledge, there has been no account of virus imaging in an orthotopic and immune-competent animal model of HCC. This is undoubtedly due to the additional inherent technical challenges associated with these models, such as rapid immune clearance of the virus and high background in the liver due to hepatic excretion of many tracers, which consequently causes strong background accumulation and unfavorable signal-to-noise-ratios for targets located in the liver. In this study, we aimed to establish a relevant system for noninvasive imaging of oncolytic VSV for orthotopic HCC in an immune-competent host. To this end, we engineered the rVSV-HSV1-sr39tk vector and demonstrated that it allows highly sensitive imaging, with minimal background in the liver setting, for accurate monitoring of virus replication via 18 F-FHBG-PET and CT. All PET data in this study were validated ex vivo by comparison with autoradiography and immunohistochemistry of the respective tissue sections. In all cases, PET and autoradiography analyses produced nearly identical tumor:liver ratios, confirming that the PET signals did indeed originate from the tumor tissue and correlate with 18 F-FHBG uptake. Furthermore, by overlaying autoradiography and immunohistochemistry from the same tissue sections, we were able to determine that patterns of tracer uptake were quite similar to those of HSV-TK expression. Although signals were not completely identical, we attribute the discrepancies to differences in sensitivity of the two methods and to the fact that the thick tissue sections (about 1 mm) used for autoradiography were subsectioned to 3 µm thickness for immunohistochemistry. As a consequence, the autoradiography data represent the average of a much thicker slice of tumor. Although we were expecting homogenously high expression of HSV-TK in the stable HSV1-sr39tk-expressing tumors, we observed sparse and patchy expression patterns by immunohistochemical analysis. This observation could be partially due to low sensitivity of the antibody used, which would result in visualization of only those cells with very high HSV-TK expression. However, we believe that this observation is an accurate reflection of the loss of signal, due to the lack of drug selection and subsequent loss of gene expression in vivo.
Moreover, the peak in PET signal detected on day 1 after virus application with a subsequent decrease on day 3 is strongly consistent with our previous studies showing the replication kinetics of VSV in orthotopic HCC tumors, with the viral titer peaking on day 1, followed by a substantial titer reduction on day 3.
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Although we have not explicitly evaluated the efficacy of the rVSV-HSV1-sr39tk virus in vivo in this study, our in vitro data demonstrated that the recombinant vector was nearly identical to the control rVSV-lacZ vector with respect to replication kinetics and tumor cell killing. Therefore, we expect that the in vivo efficacy of this recombinant vector should not be significantly altered in comparison to the rVSV-lacZ vector, which we have thoroughly demonstrated in the same HCC model used in this study. With the establishment of this sensitive and robust reporter system, the potential impact in the clinical development of oncolytic virus therapy is vast. The ability to noninvasively image viral replication in real-time will allow the clinician to apply combination or prodrug therapies at the optimal time-point with respect to the viral kinetic. Furthermore, it is expected that intratumoral VSVmediated TK signals will positively correlate to treatment outcome, and, therefore, imaging data could be potentially used as a predictive marker for therapeutic response.
An additional benefit of incorporation of HSV-TK into the VSV vector is the possibility of exploiting the transgene as a suicide gene and thereby enhancing the therapeutic effect of VSV upon application of the prodrug ganciclovir (GCV). The combination of HSV-TK and prodrug therapy has been shown to be effective in a clinical trial for HCC, 34 and synergistic tumor responses were reported as a result of VSV-mediated expression of the wt HSV-TK in combination with GCV in a mammary carcinoma and melanoma model. 35 However, since our study was exclusively focused on the characterization of the TK-reporting virus as an imaging vector, the additional therapeutic benefits conferred by combination therapies were beyond the experimental scope.
Of relevance, there is an abundance of evidence in the literature in support of the use of the sodium-iodide symporter (NIS) as an ideal reporter for virus imaging. [36] [37] [38] In particular, a recombinant VSV vector expressing NIS was used successfully for in vivo imaging in a multiple myeloma model. 33 In light of this data, our pursuit of an alternative imaging system could be justifiably questioned. Although our initial attempts did focus on the NIS reporter, and impressive uptake of radioactive iodine in rVSV-NIS-infected cells was achieved in vitro, our preliminary in vivo characterization yielded low intratumoral signals and high background (data not shown). We concluded that rVSV-NIS was not an ideal vector for in vivo imaging of therapy in our orthotopic HCC model, at least partially due to the position of the liver, which results in high background signals from endogenous NIS expression in the neighboring stomach. Therefore, we aimed to identify a reporter with low or no endogenous expression, and HSV1-sr39tk proved to be an ideal candidate.
In conclusion, in this study, we have successfully established a trackable recombinant VSV, which not only maintains its efficacy for treatment of HCC, but it enables in vivo monitoring of virus replication. We have demonstrated HSV1-sr39tk to be an ideal reporter for VSV therapy of HCC, due to strong vector-specific signals, low background, and high correlation between viral titer and the respective PET signal. This represents a major step forward in the clinical development of VSV as an oncolytic agent for HCC, as it allows for noninvasive imaging of viral therapy to monitor safety, predict therapeutic outcome, and potentially facilitate novel combination therapies. Moreover, we envision the possibility that this tool might additionally serve as a predictor of therapy outcome, as strong virus replication, resulting in elevated PET signals, could serve as a marker for therapy responses and subsequent survival benefits. Therefore, possible correlations of the initial FHBG-PET signal after rVSV-sr39tk therapy will be a major focus of our future research. Due to establishment of our imaging system in a highly challenging preclinical model, we believe our reporter system to be highly relevant and readily translatable for . All cell culture media were supplemented with 10% fetal bovine serum and 100 U/ml penicillin/streptomycin (both purchased from Biochrome AG, Berlin, Germany). All cells were kept in a humidified atmosphere at 5% CO 2 and 37 °C.
MATERIALS AND METHODS
Recombinant viruses. The HSV1-sr39tk or the lacZ gene sequences were amplified by PCR from plasmids using primers containing unique restrictions sites for XhoI and NheI for cloning into the VSV vector as an additional transcription unit at the respective cloning sites between the G-and L-protein. 39, 40 After sequence confirmation, the resulting recombinant constructs were rescued as described previously 41, 42 and plaque purified in BHK-21 cells. F-FHBG was added to each well, and cells were incubated at 37 °C for 45 minutes before washing twice with ice-cold PBS and lysing with 1 N NaOH. 18 F-FHBG uptake was measured in a γ-counter, and uptake values were normalized to the cell number.
Animal models. All animal protocols were approved by the regional governmental commission for animal protection (Regierung von Oberbayern, Munich, Germany). Male 6-to 10-week-old Buffalo rats were implanted with syngeneic Morris HCC cells. Orthotopic tumors were established as previously described, 17 and treated by intratumoral injection of 100 µl of virus or PBS on day 10, when the tumors had reached a size of 0.5-1 cm in diameter. For the subcutaneous HCC model, 10 6 cells were injected in the left (wt) or right (stable HSV1-sr39tk) shoulder. After 14 days, tumors reached a size of ~1 cm in diameter.
PET/CT imaging. Animals were imaged using a state-of-the-art smallanimal PET/CT scanner (Inveon, Siemens Medical Solutions).
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F-FHBG was prepared as previously described. 43 Image acquisition was performed 2 hours after intravenous injection of 40 MBq of 18 F-FHBG for 15 minutes under isoflurane anesthesia. PET data were reconstructed using a OSEM3D algorithm, normalized and corrected for randoms, dead time and decay. CT contrast agent ExiTron nano12000 (Miltenyi Biotec GmbH, Germany) 44 was applied 1 day before imaging (1 ml/kg i.v.). A background CT scan was performed for anatomical localization.
Image analysis. Image analysis was performed on the INVEON Research Workplace (Siemens, Knoxville, TN). CT and PET images were coregistered, and three-dimensional regions of interest (ROIs) were drawn (liver, whole tumor, spinal muscle) based on the CT image. For measuring the tumor uptake, a 50% threshold was applied (mean of the hottest 50% within the entire tumor ROI, as defined by CT image). Semiquantitative analysis was performed with mean activities from the ROIs expressed as Bq/ml and normalized to the muscle uptake.
Autoradiography.
Ex vivo autoradiography analysis of tumor, liver, and muscle was performed postimaging. Three slices of each tissue were fixed with 4% paraformaldehyde and exposed overnight to an image plate (biostep, Jahnsdorf, Germany), before scanning by an image plate scanner (CR 35 BIO, Dürr Medical, Raytest Isotopenmeßgeräte GmbH, Germany) at an internal sensitive resolution of 50 µm. Analysis was performed with AIDA Image Analyser Software (Raytest Isotopenmeßgeräte, Germany) by carefully aligning the autoradiography signal to the histology of each slice. All tissue uptake values were normalized to muscle values and are, therefore, semiquantitative.
Histology and immunohistochemistry. After autoradiography, tissues were embedded in paraffin, and serial sections were stained with hematoxylineosin (HE). Immunohistochemistry against HSV-tk (Clone 2C5.2; Bioworld Consulting Laboratories) was performed using a Dako Autostainer (Dako) after standard HIER procedure. The slides were analyzed by two blinded pathologists, and the areas of HSV-tk expression were marked. Statistical analysis. Excel (Microsoft Office) and Prism (GraphPad Software) were used for data handling, statistical analysis and graphic layout. Significance was tested by unpaired t-test, and one-tailed P values have been analyzed.
